(Reuters) -Novo Nordisk said on Wednesday it would begin selling its weight-loss drug Wegovy at a discounted price of $499 per ... The move comes just over a week after rival Eli Lilly cut the price ...

Novo Nordisk announced a direct-to-consumer program that allows patients to buy Wegovy out of pocket at a lower cost.

Novo Nordisk said it will offer all doses of Wegovy for $499 a month to patients paying cash, a bid to reach consumers who ...

Eli Lilly launched its blockbuster diabetes and weight-loss drug Mounjaro in India on Thursday, beating rival Novo Nordisk ...

Eli Lilly launched its blockbuster diabetes and weight-loss drug Mounjaro in India on Thursday, beating rival Novo Nordisk ...

Novo Nordisk said patients who are prescribed Wegovy can purchase the obesity drug ... cut the monthly price for lower-dosage vials of Zepbound by $50 for consumers who pay cash via the drugmaker ...

Novo Nordisk said on Wednesday it would begin selling its weight-loss drug Wegovy at a discounted price of $499 per month to patients paying cash, as it grapples with shifts to the competitive ...

The pharmacy, called NovoCare, will allow patients to pay $499 in cash per month for the blockbuster weight loss drug.

Both Eli Lilly’s Zepbound and Novo Nordisk’s Wegovy cost over $1,300 per month before insurance ... In response, Eli Lilly reduced the monthly price of lower-dosage vials of Zepbound by $50 for ...

NovoCare Pharmacy offers cash-paying patients the ability to schedule shipments of Wegovy directly to their home, guaranteeing individuals receive the authentic FDA-approved product.

Eli Lilly & Co. (NYSE: LLY) shares are trading higher Thursday after the company launched its weight-loss drug Mounjaro in ...

Eli Lilly has launched its diabetes and weight-loss drug, Mounjaro, in India, outpacing competitor Novo Nordisk. With ...